All In Biotech

Drug Trial Radar · NCT01436149

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,262

Actual

Start

Oct 27, 2011

Primary completion

Dec 23, 2013

Study completion Dec 23, 2013

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can supplemental SPD489 help patients who still have residual depression symptoms while taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Conditions

  • Major Depressive Disorder

Interventions

  • SPD489 (Lisdexamfetamine dimesylate )Drug

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks

  • PlaceboDrug

    Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 WeeksTime frame: 8 weeks

Locations

85 sites in 6 countries. Site status is shown where the registry gives one.

  • Birmingham Research Group

    Birmingham, Alabama

  • AV Institue, Inc.

    Carson, California

  • University of California, Irvine Child Development Center

    Irvine, California

  • South Coast Clinicals

    Norwalk, California

  • North County Clinical Research

    Oceanside, California

  • Pasadena Research Institute, LLC

    Pasadena, California

  • Affiliated Research Institute

    San Diego, California

  • Clinical Innovations, Inc.

    San Diego, California

  • Sharp Mesa Vista Hospital

    San Diego, California

  • Geriatric and Adult Psychiatry, LLC

    Hamden, Connecticut

  • Middlexex Hospital Center for Behavioral Health

    Middletown, Connecticut

  • CNS Clinical Research Group

    Coral Springs, Florida

  • Emerald Coast Mood & Memory, PA

    Fort Walton Beach, Florida

  • Florida Clinical Research Center, LLC.

    Maitland, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Compass Research, LLC

    Orlando, Florida

  • Meridien Research

    St. Petersburg, Florida

  • Stedman Clinical Trials

    Tampa, Florida

  • Carman Research

    Smyrna, Georgia

  • American Medical Research, Inc.

    Oak Brook, Illinois

  • The Davis Clinic

    Indianapolis, Indiana

  • Northwest Indiana Center for Clinical Research

    Valparaiso, Indiana

  • MCM Clinical Research LLC

    Florence, Kentucky

  • Pharmasite Research, Inc.

    Baltimore, Maryland

  • Potomac Grove Clinical Research Center

    Gaithersburg, Maryland

  • Office of Marc Hertzman, MD

    Rockville, Maryland

  • Adams Clinical Trials, LLC

    Watertown, Massachusetts

  • St. Charles Psychiatric Associates - Midwest Research Group

    Saint Charles, Missouri

  • Bioscience Research, LLC

    Mount Kisco, New York

  • Fieve Clinical Research

    New York, New York

  • Richmond Behavioral Associates

    Staten Island, New York

  • Triangle Neuropsychiatry

    Durham, North Carolina

  • Rcihard H. Weisler, MD, PA & Associates

    Raleigh, North Carolina

  • Community Research

    Cincinnati, Ohio

  • Lindner Center of HOPE

    Mason, Ohio

  • SP Research, PLLC

    Oklahoma City, Oklahoma

  • Summit Research Network (Oregon) Inc.

    Portland, Oregon

  • Paramount Clinical Research

    Bridgeville, Pennsylvania

  • Suburban Research Associates

    Media, Pennsylvania

  • CRI Worldwide LLC

    Philadelphia, Pennsylvania

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.